Delivery of large molecules via poly(butyl cyanoacrylate) nanoparticles into the injured rat brain

Poly(n-butyl-2-cyanoacrylate) (PBCA) nanoparticles have been successfully applied to deliver small-molecule drugs to the central nervous system (CNS). However, it is unclear whether PBCA nanoparticles can be used as the delivery system for large molecules to potentially treat traumatic brain injury (TBI). In this study, we tested the capacity of PBCA nanoparticles in passing through the blood-brain barrier (BBB) and transporting large molecules into normal and injured brains in the rat. We first synthesized PBCA nanoparticles by dispersion polymerization and then loaded the particles with either horseradish peroxidase (HRP, 44 kDa) or enhanced green fluorescent protein (EGFP, 29 kDa), which were further coated with polysorbate 80. Next, the polysorbate 80-coated HRP or EGFP-loaded PBCA nanoparticles were intravenously injected into the normal and brain-injured rats. We found that, at 45 min after injection, PBCA nanoparticle-delivered HRP or EGFP was hardly detected in the normal brains of the rats, but a small amount of EGFP carried by PBCA nanoparticles was noted in the normal brains 48 h after administration, which was further confirmed by immunolocalization with anti-EGFP antibodies. In contrast, at 4 h after TBI with a circulation time of 45 min, although the penetration of HRP or EGFP alone was hampered by the BBB, the PBCA nanoparticle-delivered HRP or EGFP was widely distributed near injured sites. Together, our findings provide histological evidence that PBCA nanoparticles can be used as an efficient delivery system for large molecules to overcome the barrier in the brain with TBI.

[1]  K. Jain,et al.  Nanobiotechnology-Based Drug Delivery to the Central Nervous System , 2007, Neurodegenerative Diseases.

[2]  P. Kochanek,et al.  Blood brain barrier permeability and acute inflammation in two models of traumatic brain injury in the immature rat: a preliminary report. , 1998, Acta neurochirurgica. Supplement.

[3]  N. Soehendra,et al.  N-Butyl-2-Cyanoacrylate: A Supplement to Endoscopic Sclerotherapy , 1987, Endoscopy.

[4]  D. Begley,et al.  Direct Evidence That Polysorbate-80-Coated Poly(Butylcyanoacrylate) Nanoparticles Deliver Drugs to the CNS via Specific Mechanisms Requiring Prior Binding of Drug to the Nanoparticles , 2003, Pharmaceutical Research.

[5]  B. Hyman,et al.  Nanoparticles enhance brain delivery of blood–brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging , 2011, Proceedings of the National Academy of Sciences.

[6]  R. Hayes,et al.  Nerve Growth Factor Attenuates Cholinergic Deficits Following Traumatic Brain Injury in Rats , 1997, Experimental Neurology.

[7]  C. Ek,et al.  Changes in blood–brain barrier permeability to large and small molecules following traumatic brain injury in mice , 2007, The European journal of neuroscience.

[8]  D D Allen,et al.  Nanoparticle Technology for Drug Delivery Across the Blood-Brain Barrier , 2002, Drug development and industrial pharmacy.

[9]  L. Fenart,et al.  Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier. , 1999, The Journal of pharmacology and experimental therapeutics.

[10]  A. Vertegel,et al.  Proteins conjugated to poly(butyl cyanoacrylate) nanoparticles as potential neuroprotective agents , 2011, Biotechnology and bioengineering.

[11]  Richard Madsen,et al.  Osmotic blood-brain barrier disruption and chemotherapy in the treatment of high grade malignant glioma: patient series and literature review , 2004, Journal of Neuro-Oncology.

[12]  H. Bramlett,et al.  Alterations in blood-brain barrier permeability to large and small molecules and leukocyte accumulation after traumatic brain injury: effects of post-traumatic hypothermia. , 2009, Journal of neurotrauma.

[13]  Peter Ramge,et al.  Apolipoprotein-mediated Transport of Nanoparticle-bound Drugs Across the Blood-Brain Barrier , 2002, Journal of drug targeting.

[14]  J. Ghajar Traumatic brain injury , 2000, The Lancet.

[15]  Joo-Hiuk Son,et al.  Principle and applications of terahertz molecular imaging , 2013, Nanotechnology.

[16]  William Couet,et al.  Indirect Evidence that Drug Brain Targeting Using Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles Is Related to Toxicity , 1999, Pharmaceutical Research.

[17]  W. D. de Jong,et al.  Drug delivery and nanoparticles: Applications and hazards , 2008, International journal of nanomedicine.

[18]  M. Kupersmith,et al.  The effect of embolization with N-butyl cyanoacrylate prior to surgical resection of cerebral arteriovenous malformations. , 1993, Journal of neurosurgery.

[19]  M. Setou,et al.  Functionalized magnetic nanoparticles as an in vivo delivery system. , 2009, Methods in molecular biology.

[20]  E. Hansson,et al.  Astrocyte–endothelial interactions at the blood–brain barrier , 2006, Nature Reviews Neuroscience.

[21]  N. Behan,et al.  Poly n-butyl cyanoacrylate nanoparticles: a mechanistic study of polymerisation and particle formation. , 2001, Biomaterials.

[22]  G. Fricker,et al.  Delivery of nanoparticles to the brain detected by fluorescence microscopy. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[23]  D. A. Kharkevich,et al.  Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles , 1995 .

[24]  D. Stein,et al.  Blood-brain barrier breakdown and edema formation following frontal cortical contusion: does hormonal status play a role? , 1995, Journal of neurotrauma.

[25]  Hartwig Wolburg,et al.  Tight junctions of the blood-brain barrier: development, composition and regulation. , 2002, Vascular pharmacology.

[27]  D. A. Kharkevich,et al.  Delivery of Loperamide Across the Blood-Brain Barrier with Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles , 1997, Pharmaceutical Research.

[28]  E. Neuwelt,et al.  Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. , 1998, Neurosurgery.

[29]  A. Marmarou,et al.  The permissive nature of blood brain barrier (BBB) opening in edema formation following traumatic brain injury. , 2000, Acta neurochirurgica. Supplement.

[30]  Jayanth Panyam,et al.  Biodegradable nanoparticles for drug and gene delivery to cells and tissue. , 2003, Advanced drug delivery reviews.

[31]  Drug targeting to the brain. , 2007, Annual review of pharmacology and toxicology.

[32]  C. Werner,et al.  Pathophysiology of traumatic brain injury. , 2007, British journal of anaesthesia.

[33]  Brian Y. Hwang,et al.  Adjuvant Embolization With N-Butyl Cyanoacrylate in the Treatment of Cerebral Arteriovenous Malformations: Outcomes, Complications, and Predictors of Neurologic Deficits , 2009, Stroke.

[34]  Y. Katayama,et al.  Matrix metalloproteinase-9 is associated with blood-brain barrier opening and brain edema formation after cortical contusion in rats. , 2006, Acta neurochirurgica. Supplement.

[35]  Gordon L. Amidon,et al.  The Mechanism of Uptake of Biodegradable Microparticles in Caco-2 Cells Is Size Dependent , 1997, Pharmaceutical Research.

[36]  I. Sukhotnik,et al.  Use of N-butyl-2-cyanoacrylate in elective surgical incisions--longterm outcomes. , 1999, Journal of the American College of Surgeons.

[37]  J. Hainfellner,et al.  Tissue reactions induced by different embolising agents in cerebral arteriovenous malformations: a histopathological follow‐up , 2006, Pathology.

[38]  R. Egleton,et al.  Mannitol opening of the blood–brain barrier: regional variation in the permeability of sucrose, but not 86Rb+ or albumin , 2004, Brain Research.

[39]  L. Noble,et al.  Traumatic brain injury in the rat: Characterization of a lateral fluid-percussion model , 1989, Neuroscience.

[40]  T. Davis,et al.  The Blood-Brain Barrier/Neurovascular Unit in Health and Disease , 2005, Pharmacological Reviews.

[41]  Ram B. Gupta,et al.  Fundamentals of Drug Nanoparticles , 2006 .

[42]  A. Kabanov,et al.  Novel Nanomaterials for Clinical Neuroscience , 2008, Journal of Neuroimmune Pharmacology.

[43]  H. Fenniri,et al.  Nanotechnology-based drug delivery systems , 2007, Journal of occupational medicine and toxicology.

[44]  K R Maravilla,et al.  Osmotic blood-brain barrier disruption: Computerized tomographic monitoring of chemotherapeutic agent delivery , 1979 .

[45]  J. Kreuter,et al.  Significant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles , 1999, Pharmaceutical Research.